AR050250A1 - Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica - Google Patents
Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeuticaInfo
- Publication number
- AR050250A1 AR050250A1 ARP050102107A ARP050102107A AR050250A1 AR 050250 A1 AR050250 A1 AR 050250A1 AR P050102107 A ARP050102107 A AR P050102107A AR P050102107 A ARP050102107 A AR P050102107A AR 050250 A1 AR050250 A1 AR 050250A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- cyano
- nitro
- hydroxy
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Compuesto de formula (1), en a cual: n puede tomar un valor de 1 a 6; -(C)n- representa un grupo alquilideno-C1-6, eventualmente substituído por 1 a 4 substituyentes, elegidos entre un átomo de halogeno, un grupo hidroxi, nitro, ciano, amino, monoalquilamino-C1-3, dialquilamino-C2-6 o alcoxi-C1-3; R1 - representa un átomo de hidrogeno; - un grupo alquilo-C1-6; R2 representa - un átomo de hidrogeno; - un grupo alquilo-C1-6 o cicloalquilo-C3-6 eventualmente substituídos por 1 a 4 substituyentes elegidos entre un átomo de halogeno, un grupo hidroxi, nitro, ciano, amino, monoalquilamino-C1-3, dialquilamino-C2-6, perhalogenoalquilo-C1-2, halogenoalquilo-C1-3, alcoxi-C1-3, cicloalquilo-C3-6, un heteroarilo monocíclico tal como un tienilo, furilo o prirolilo o un arilo,tal como un fenilo o un naftilo; el arilo está eventualente substituído por 1 a 4 substituyentes elegidos entre un átomo de halogeno, un grupo hidroxi, nitro, ciano, amino, monoalquilamino-C1-3, dialquilamino-C2-6, alquilo-C1-3, perhalogenoalquilo-C1-2, halogenoalquilo-C1-3, alcoxi-C1-3 o un grupo alquilidendioxi-C1-3; B representa - NR3R4; R3 y R4 representan, independientemente entre sí, un grupo alquilo-C1-6, un átomo de hidrogeno; o - R3 y R4 representan juntos, un grupo alquilideno-C1-6, un grupo alquenilideno-C2-8, un grupo alquilideno-C1-3-O-alquilideno-C1-3, o un grupo alquilideno-C1-3-N(R5)-alquilideno-C1-3, donde R5 representa un átomo de hidrogeno, un grupo alquilo-C1-3 o alquilcarbonilo-C1-6, y esos grupos alquilo-C1-3 y alquilcarbonilo-C1-6 pueden ser sustituídos por un átomo de halogeno, un grupo hidroxi, alcoxi-C1-3, nitro, ciano o amino; o - un aminociclo, unido por medio de un carbono, al grupo -NR1-(C)n-, tal como aziridina, azetidina, pirrolidina, piperidina o morfolina; los grupos R3, R4, así como el amonociclo están substituídos, eentualmente, por 1 a 4 substituyentes elegidos entre un fenilo, un bencilo, un átomo de halogeno, un grupo hidroxi, nitro, ciano, amino, monoalquilamino-C1-3, dialquilamino-C2-6, alquilo-C1-3, o alcoxi-C1-3; y el átomo de nitrogeno está substituído, eventualmente, por un alquilo-C1-3, en estado de base o de sal de adicion con un ácido, así como en estado de hidrato o de solvato.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0405607A FR2870846B1 (fr) | 2004-05-25 | 2004-05-25 | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050250A1 true AR050250A1 (es) | 2006-10-11 |
Family
ID=34944870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102107A AR050250A1 (es) | 2004-05-25 | 2005-05-23 | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica |
Country Status (41)
Country | Link |
---|---|
US (3) | US7833999B2 (es) |
EP (1) | EP1753725B1 (es) |
JP (1) | JP4861979B2 (es) |
KR (1) | KR101176675B1 (es) |
CN (1) | CN1956962B (es) |
AR (1) | AR050250A1 (es) |
AU (1) | AU2005250197B2 (es) |
BR (1) | BRPI0511581A (es) |
CA (1) | CA2565293C (es) |
CR (1) | CR8735A (es) |
CY (1) | CY1114240T1 (es) |
DK (1) | DK1753725T3 (es) |
DO (1) | DOP2005000103A (es) |
EA (1) | EA010234B1 (es) |
EC (1) | ECSP067020A (es) |
ES (1) | ES2407140T3 (es) |
FR (1) | FR2870846B1 (es) |
GT (1) | GT200500126A (es) |
HK (1) | HK1106229A1 (es) |
HN (1) | HN2005000239A (es) |
HR (1) | HRP20130431T1 (es) |
IL (1) | IL179021A (es) |
JO (1) | JO2877B1 (es) |
MA (1) | MA28720B1 (es) |
MX (1) | MXPA06013629A (es) |
MY (1) | MY148980A (es) |
NI (1) | NI200600279A (es) |
NO (1) | NO338104B1 (es) |
NZ (1) | NZ551509A (es) |
PA (1) | PA8634501A1 (es) |
PE (1) | PE20060273A1 (es) |
PL (1) | PL1753725T3 (es) |
PT (1) | PT1753725E (es) |
SI (1) | SI1753725T1 (es) |
SV (1) | SV2006002126A (es) |
TN (1) | TNSN06356A1 (es) |
TW (1) | TWI360540B (es) |
UA (1) | UA84771C2 (es) |
UY (1) | UY28917A1 (es) |
WO (1) | WO2005118547A1 (es) |
ZA (1) | ZA200609820B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
EP1790646A1 (fr) * | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
DK2221298T3 (da) | 2007-11-13 | 2013-11-18 | Taisho Pharmaceutical Co Ltd | Phenylpyrazolderivater |
TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
CN102803247B (zh) * | 2009-06-26 | 2014-11-05 | 赛诺菲 | 组胺h3受体拮抗剂的新颖富马酸盐 |
AR080375A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida |
BR112014013461A2 (pt) | 2011-12-08 | 2017-06-13 | Taisho Pharmaceutical Co Ltd | derivado de fenilpirrol |
US20150045553A1 (en) | 2011-12-27 | 2015-02-12 | Taisho Pharmaceutical Co., Ltd | Phenyltriazole derivative |
EP2647377A1 (en) * | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
WO2015032966A1 (en) * | 2013-09-09 | 2015-03-12 | Sanofi | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
CN110642854A (zh) * | 2019-11-20 | 2020-01-03 | 成都克莱蒙医药科技有限公司 | 一种稠环化合物的多晶型、其组合物、制备方法及其应用 |
EP4251148A1 (en) | 2020-11-27 | 2023-10-04 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7102394A (en) * | 1993-06-09 | 1995-01-03 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
GB9508622D0 (en) * | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
WO1997029092A1 (en) * | 1996-02-09 | 1997-08-14 | James Black Foundation Limited | Histamine h3 receptor ligands |
SK15072000A3 (sk) | 1998-04-10 | 2001-08-06 | Japan Tobacco Inc. | Amidové zlúčeniny |
CA2374646A1 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
KR100554813B1 (ko) | 2001-01-02 | 2006-02-22 | 에프. 호프만-라 로슈 아게 | 알파 1에이/비 아드레날린성 수용체 길항제로서의퀴나졸론 유도체 |
EP1379493A2 (en) * | 2001-03-23 | 2004-01-14 | Eli Lilly and Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
JP2005513154A (ja) * | 2001-12-26 | 2005-05-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 尿素誘導体 |
JP2003192660A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
EP1484366B1 (en) | 2002-03-08 | 2012-07-25 | Sakata Inx Corporation | Treated pigment, use thereof, and compound for treating pigment |
GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
NZ538932A (en) * | 2002-08-29 | 2007-04-27 | Boehringer Ingelheim Pharma | 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease |
AU2004279855A1 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
WO2005040135A1 (ja) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
EP1630158A1 (en) | 2004-08-18 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
EP1630159A1 (en) | 2004-08-18 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
US20080261999A1 (en) | 2005-03-04 | 2008-10-23 | Fionna Mitchell Martin | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists |
EP1790646A1 (fr) * | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
-
2004
- 2004-05-25 FR FR0405607A patent/FR2870846B1/fr not_active Expired - Lifetime
-
2005
- 2005-05-23 PE PE2005000566A patent/PE20060273A1/es not_active Application Discontinuation
- 2005-05-23 JO JO200571A patent/JO2877B1/en active
- 2005-05-23 HN HN2005000239A patent/HN2005000239A/es unknown
- 2005-05-23 AR ARP050102107A patent/AR050250A1/es not_active Application Discontinuation
- 2005-05-24 DK DK05772938.6T patent/DK1753725T3/da active
- 2005-05-24 GT GT200500126A patent/GT200500126A/es unknown
- 2005-05-24 AU AU2005250197A patent/AU2005250197B2/en not_active Ceased
- 2005-05-24 MY MYPI20052337A patent/MY148980A/en unknown
- 2005-05-24 CN CN200580016856.7A patent/CN1956962B/zh active Active
- 2005-05-24 JP JP2007514007A patent/JP4861979B2/ja active Active
- 2005-05-24 UY UY28917A patent/UY28917A1/es not_active Application Discontinuation
- 2005-05-24 TW TW094116907A patent/TWI360540B/zh not_active IP Right Cessation
- 2005-05-24 UA UAA200613640A patent/UA84771C2/uk unknown
- 2005-05-24 BR BRPI0511581-7A patent/BRPI0511581A/pt not_active Application Discontinuation
- 2005-05-24 EA EA200602176A patent/EA010234B1/ru not_active IP Right Cessation
- 2005-05-24 KR KR1020067024780A patent/KR101176675B1/ko active IP Right Grant
- 2005-05-24 MX MXPA06013629A patent/MXPA06013629A/es active IP Right Grant
- 2005-05-24 EP EP05772938A patent/EP1753725B1/fr active Active
- 2005-05-24 CA CA2565293A patent/CA2565293C/fr not_active Expired - Fee Related
- 2005-05-24 PT PT57729386T patent/PT1753725E/pt unknown
- 2005-05-24 ES ES05772938T patent/ES2407140T3/es active Active
- 2005-05-24 PL PL05772938T patent/PL1753725T3/pl unknown
- 2005-05-24 NZ NZ551509A patent/NZ551509A/en not_active IP Right Cessation
- 2005-05-24 SI SI200531708T patent/SI1753725T1/sl unknown
- 2005-05-24 SV SV2005002126A patent/SV2006002126A/es active IP Right Grant
- 2005-05-24 ZA ZA200609820A patent/ZA200609820B/xx unknown
- 2005-05-24 WO PCT/FR2005/001279 patent/WO2005118547A1/fr active Application Filing
- 2005-05-25 DO DO2005000103A patent/DOP2005000103A/es unknown
- 2005-05-25 PA PA20058634501A patent/PA8634501A1/es unknown
-
2006
- 2006-11-02 IL IL179021A patent/IL179021A/en not_active IP Right Cessation
- 2006-11-03 TN TNP2006000356A patent/TNSN06356A1/en unknown
- 2006-11-07 CR CR8735A patent/CR8735A/es unknown
- 2006-11-15 US US11/559,929 patent/US7833999B2/en active Active
- 2006-11-22 EC EC2006007020A patent/ECSP067020A/es unknown
- 2006-11-23 NI NI200600279A patent/NI200600279A/es unknown
- 2006-12-04 MA MA29510A patent/MA28720B1/fr unknown
- 2006-12-19 NO NO20065918A patent/NO338104B1/no not_active IP Right Cessation
-
2007
- 2007-10-24 HK HK07111466.5A patent/HK1106229A1/xx not_active IP Right Cessation
-
2010
- 2010-10-08 US US12/901,063 patent/US8273733B2/en active Active
-
2012
- 2012-08-24 US US13/593,832 patent/US8524700B2/en active Active
-
2013
- 2013-05-16 HR HRP20130431TT patent/HRP20130431T1/hr unknown
- 2013-05-24 CY CY20131100411T patent/CY1114240T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050250A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica | |
AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
NO20074391L (no) | CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter | |
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
BRPI0514644A (pt) | composto fosforamidita, composto ácido ribonucléico, e método para produzir oligo-rna | |
EA200970171A1 (ru) | Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
AR050283A1 (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeuticas. | |
AR053342A1 (es) | Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas | |
AR052450A1 (es) | Derivados de n-(heteroaril)-1h- indol-2-carboxamidas , supreparacion y su aplicacion en terapeutica | |
EA200500240A1 (ru) | Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
AR044906A1 (es) | Derivados de difenilpiridina, su preparacion y su aplicacion en terapeutica | |
DK1970372T3 (da) | Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler | |
AR040570A1 (es) | Deriados de acilaminotiazol, su preparacion y su aplicacion en terapeutica | |
AR053721A1 (es) | Benzonitrilos como moduladores del receptor de androgenos | |
EA200800149A1 (ru) | 4,5-диарилпиррольные производные, способ их получения и применение в терапии | |
AR075838A1 (es) | Derivados de n-((6-aza-biciclo(3.2.1)oct-5-il)-aril-metil)-heterobenzamida, su preparacion y su aplicacion en terapeutica. | |
AR057615A1 (es) | Derivados de isoquinolina y benzo (h) isoquinolina su preparcion y su utilizacion en terapeutica | |
EA200700179A1 (ru) | Производные пиррола, их получение и их применение в терапии | |
EA200500716A1 (ru) | Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат | |
AR040276A1 (es) | Derivados de 3-(4-oxo-4h-cromen-2-il)-(1h)-quinolein-4-onas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |